Persistent COVID-19 lung infection in a child with a primary immunodeficiency

Sarah Fernández-Suárez,1,2 Giuliana Reyes-Florian,1,3 Pablo Vásquez-Hoyos,4,5 Jesús Angel Domínguez-Rojas 1,6

SUMMARY
SARS-CoV-2 infection in children with primary immunodeficiency disease (PID) and its complications have not yet been well described, the course of COVID-19 can range from mild illness to death. We aim to report the case of a child with a PID who develop a severe and persistent pulmonary COVID-19 infection. We present chronologically his clinical course, tests, interventions and radiological findings showing his irregular evolution and poor response to infection. This case highlights the need to accurately monitor the immune response in these cases to try to stop the progression of the damage.

BACKGROUND
We are currently facing the COVID-19 pandemic that has generated devastating morbidity and mortality rates and where patients with comorbidities are the most susceptible to developing severe forms due to impaired respiratory function or due to systemic inflammatory response syndrome.1

Immunosuppressed individuals are highly susceptible to dying from bacterial pathogens and to their quality of life changing through progressive chronic diseases that affect multiple systems and are frequently associated with autoimmune and malignant disorders. As a group, they are highly susceptible to the current pandemic.2

As we learn more about the disease course of SARS-CoV-2 in patients with different primary immunodeficiencies (PID), it is likely that we will gain valuable information about the immune system response to COVID-19.3

We report on a child with PID who developed a persistent COVID-19 lung infection. We present chronologically its clinical evolution, tests, interventions and radiological findings showing its irregular development and poor response to infection.

CASE PRESENTATION
This is a 12-year-old mestizo schoolboy from the province of Huancavelica-Peru, who from the first year of life has a diagnosis of PID due to a mutation in the LRBA gene (exon 5 and 36), an older sister with agammaglobulinaemia, and a history of multiple hospital admissions for recurrent pneumonia with mild pulmonary sequelae (bronchiectasis) and medicated with human intravenous immunoglobulin once a month at a dose of 800 mg per kg from the age of 10 years.

He was admitted to our emergency room in Lima-Peru, with a 10-day history of persistent cough and fever and had had a previous exposure with his mother who tested positive for SARS-CoV-2 25 days before this admission. On arrival, his oxygen saturation (SpO2) was 92% in room air and he was positive for SARS-CoV-2 by Reverse transcription polymerase chain reaction (RT-PCR) with a negative antibody test (quantitative IgG and IgM ELISA for the S1 subunit of the SARS-CoV-2 spike protein and also a quantitative electrochemiluminescence immunoassay for total antibody to nucleocapsid (N) antigen). He was admitted for COVID-19 pneumonia, and started on antibiotics and received an early intravenous immunoglobulin dose (800 mg per kg) with slow clinical improvement and was discharged on day 18.

Two days later, he was readmitted to the emergency department, for severe respiratory distress (SpO2 of 74% on room air), with signs of circulatory collapse and a persistently positive RT-PCR for SARS-CoV-2 and a persistently negative antibody test. The images showed new bilateral infiltrates and ground glass appearance with bronchiectasis compatible with COVID-19 pneumonia (figure 1) and also he had increased levels of inflammation markers, but did not meet the criteria for multisystem inflammatory syndrome (table 1). Due to his clinical deterioration, he required mechanical ventilation and vasoactive support and was transferred to the paediatric intensive care unit where he received broad-spectrum antibacterial and antifungal coverage as well as dexamethasone at 0.15 mg per kg per day for 1 week. The bronchoalveolar lavage (BAL) culture showed growth of Stenotrophomonas maltophilia and Candida albicans, for which the therapy was adjusted to intravenous trimethoprim–sulfamethoxazole and fluconazole for 15 days with a new control BAL culture without growth. Smear and culture of acid-fast bacilli, Pneumocystis jiroveci stain and galactomannan test were all negative. During his hospital stay, RT-PCR SARS-CoV-2 remained persistently positive and received another dose of intravenous immunoglobulin on day 20 of illness (800 mg per kg). After several days, a partial clinical improvement was observed and we were able to wean him initially to a high-flow nasal cannula (HFNC) and then to slow flow oxygen. He was transferred to the general ward, but again developed respiratory distress and had to be put back on HFNC with slow weaning. He received another dose of intravenous immunoglobulin, and after we were able to support him with low flow oxygen.

OUTCOME AND FOLLOW-UP
After 6 weeks, the RT-PCR SARS-CoV-2 was finally negative but with no changes in antibodies, persisted
with mild respiratory distress, wheezing rales in both lung fields and required oxygen therapy with a reservoir mask at 5 L/min. On neurological examination, he showed signs of muscle atrophy and decreased strength predominantly in the lower limbs with a one-fifth on the left and two-fifths on the right. The last tomographic images showed severe pulmonary sequelae (figure 2). He was eventually discharged with home support and may require a lung and bone marrow transplant in the future. Figure 3 summarises the timeline during his care.

**DISCUSSION**

An effective immune response against SARS-CoV-2 is decisive for its control. Within the immunopathogenes of SARS-CoV-2, it has been reported that macrophages, after being infected, present antigens to T cells that lead to their activation, differentiation and production of cytokines associated with the different subsets of T cells. B lymphocytes are instructed to produce high-affinity antibodies against SARS-CoV-2 epitopes.

Some authors have postulated that in PID cases, the intrinsic lack of B cells would prevent the development of the entire inflammatory cascade by SARS-CoV-2, which would make them less likely to develop or experience a serious infection due to a defect in their immune system. However, the evidence is still extremely limited and does not allow us to conclude whether an immunodeficiency is a protective or aggravating factor for COVID-19.

The largest report comes from Delavari et al. Using the registry database hosted at the Children’s Medical Center (Tehran, Iran) that among the 4717 registered patients, 19 reported a positive RT-PCR SARS-CoV-2 test showing an infection rate similar to that of the region, but with a 10-fold increase in deaths in PID cases (8 deaths, 42%).

In general, reports are scarce and the clinical pictures varied, we highlight some. A report of two patients with X-linked agammaglobulinemia showed that they developed SARS-CoV-2 interstitial pneumonia with fever, cough and anorexia and had elevated CRP and ferritin levels, but never required mechanical ventilation with or intensive care.

Other examples are reported in cases of common variable immunodeficiency, which is the most symptomatic PID presenting with hypogammaglobulinemia, recurrent infections and poor response to vaccines. Aljaberi and Wishah present an adult patient who developed a severe form of COVID-19 pneumonia and required treatment with mechanical ventilation. He also received antibiotics, hydroxychloroquine and high doses of immunoglobulin, with a favourable resolution with a brief hospitalisation. Another case also presented an adult with a fatal outcome due to severe COVID-19 pneumonia, but this case did not receive regular immunoglobulin infusions at the time of infection.

Intravenous immunoglobulin has been proposed as an immunomodulatory and anti-inflammatory treatment, especially if given in higher doses, and for patients with PID, it would also work to compensate for the lack of adequate antibody production with better evidence if instituted early. In our case, we only observed mild lymphopenia after administration without additional adverse effects such as fever or seizures. Although we noticed a clinical improvement when applied, it is possible that this also decreased the natural response of the host and perpetuates susceptibility to the virus.

We considered all this in our patient as part of the established hospital treatment, and its limitation was the lack of positive antibody response to SARS-CoV-2, which can be a false-negative result. We also believe that in this case the infection persisted, as evidenced by the positive detection by SARS-CoV-2 viral RNA by RT-PCR and its clinical and imaging behaviour consistent with severe COVID-19 pneumonia.

In cases of COVID-19, the severity of the disease can be increased due to impaired cellular immunity, poor viral control and in the case of immune regulation, uncontrolled inflammatory responses.
responses may also make patients more susceptible to COVID-19. While the new evidence indicates that RT-PCR positivity may persist for several weeks after recovery and that this does not necessarily imply the presence of viable or transmissible virus.

Our patient presented clinical deterioration and two hospital admissions as a consequence of the prolonged course of the disease associated with the persistence of positive SARS-CoV-2 RT-PCR and negative antibodies test for 6 weeks even with treatment with exogenous human immunoglobulins. Currently, we do not have tocilizumab and there is no availability of convalescent plasma in children with COVID-19.

These data have some limitations as it is not part of a research protocol, but real-life information that is not collected in a systematic way, which limits the search for potentially confusing cofactors and limits the interpretation of the case. For example, the RT-PCRs were performed by the National Institute of Health of Peru and are reported only as positive or negative only, the cycle threshold was not available to correlate those viral loads with disease state.

CONCLUSION

Given the limited evidence to date, the behaviour of SARS-CoV-2 infection and the persistence of SARS-COV-2 RT-PCR in patients with PID is unclear, and current as studies have shown variable results in these patients so far, we need more information on how to approach these cases.

Learning points

- Children with a primary immunodeficiency may be at increased risk of developing severe and persistent COVID-19.
- RT-PCR SARS-CoV-2 in these patients should be frequently monitored for a decision on isolation and may represent persistent infectivity.
- SARS-CoV-2 antibodies may not be useful for follow-up in case where intravenous immunoglobulin is used.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Parental/guardian consent obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iDs
Pablo Vásquez-Hoyos http://orcid.org/0000-0002-4892-5032
Jesús Angel Domínguez-Rojas http://orcid.org/0000-0001-6141-6622

REFERENCES

1. Pastrian-Soto G, Pastrian-Soto G. Bases genéticas y moleculares del COVID-19 (SARS-CoV-2), mecanismos de patogénesis y de respuesta inmune [genetic and molecular basis of COVID-19 (SARS-CoV-2) mechanisms of pathogenesis and immune]. Int. J. Odontostomat 2020;14:331–7.

2. Petricau C, Nedeľea I, Deleanu D. Surprising protective mechanisms against severe forms of COVID-19 infection among common variable immunodeficiency patients: one center experience. Research Square (Preprint) 2020.

3. Fill L, Hadney L, Graven K, et al. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125:112–4.

4. de León Delgado J, Pareja Cruz A, Aguilar Ramírez P. SARS-CoV-2 y sistema inmune: una batalla de titanes [SARS-CoV-2 and the immune system: a battle of titans]. Horiz. Med 2020;20:e1209.

5. García-Salido A. Revisión narrativa sobre la respuesta inmunaria frente a un coronavirus: descripción general, aplicabilidad para SARS-CoV-2 e implicaciones terapéuticas [narrative review of the immune response against coronavirus: an overview, applicability for SARS-CoV-2, and therapeutic implications]. An Pediatr 2020;93:60.e1–60.e7.

6. Babah A, Rezaei N. Primary immunodeficiency diseases in COVID-19 pandemic: a predisposing or protective factor? Am J Med Sci 2020;360:740–1.

7. Delavari S, Abolhassani H, Abolnozhdan F, et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. J Clin Immunol 2021;41:345–55.

8. Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol 2020;31:565–57.

9. Aljaberi R, Wishah K. Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. Ann Allergy Asthma Immunol 2020;125:349–50.

10. Muller J, Wang A, Feldweg A. A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency. J Allergy Immunol 2021;126:90–2.
Case report

11 Hammarström L, Abolhassani H, Baldanti F, et al. Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective. J Allergy Clin Immunol 2020;146:58–60.

12 Yuan B, Liu H-Q, Yang Z-R, et al. Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation. Sci Rep 2020;10:11887.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow